Oppenheimer & Co. Inc. Decreases Position in Celldex Therapeutics, Inc. (CLDX)
Oppenheimer & Co. Inc. lowered its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 37.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 59,995 shares of the biopharmaceutical company’s stock after selling 35,951 shares during the period. Oppenheimer & Co. Inc.’s holdings in Celldex Therapeutics were worth $172,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently made changes to their positions in CLDX. BB&T Securities LLC acquired a new position in Celldex Therapeutics in the 2nd quarter valued at about $117,000. Voya Investment Management LLC grew its stake in Celldex Therapeutics by 17.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 7,499 shares during the last quarter. Overbrook Management Corp acquired a new position in Celldex Therapeutics in the 2nd quarter valued at about $139,000. Pacad Investment Ltd. acquired a new position in Celldex Therapeutics in the 2nd quarter valued at about $150,000. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Celldex Therapeutics during the 2nd quarter worth approximately $158,000. Institutional investors and hedge funds own 52.55% of the company’s stock.
CLDX has been the topic of a number of analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. HC Wainwright set a $10.00 target price on shares of Celldex Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, ValuEngine lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Three research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. Celldex Therapeutics currently has an average rating of “Hold” and an average target price of $6.31.
Celldex Therapeutics, Inc. (CLDX) opened at $2.90 on Wednesday. Celldex Therapeutics, Inc. has a 52-week low of $2.20 and a 52-week high of $4.07.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The firm had revenue of $3.90 million for the quarter, compared to analyst estimates of $1.30 million. During the same quarter in the prior year, the business posted ($0.29) EPS. The business’s revenue was up 77.3% compared to the same quarter last year. equities research analysts predict that Celldex Therapeutics, Inc. will post -0.93 earnings per share for the current year.
Celldex Therapeutics Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.